Jefferies Upgrades Summit Therapeutics to Buy, Raises Price Target to $25

Benzinga Newsdesk www.benzinga.com Positive 85.7%

Neg 0% Neu 0% Pos 85.7%

Jefferies analyst Faisal Khurshid upgrades Summit Therapeutics (NASDAQ:SMMT) from Hold to Buy and raises the price target from $15 to $25.